Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Genetic engineering creates new opportunities In the early 1970s a new tool appeared on the scene called recombinant DNA technology or genetic engineering
(Candidacy & Contraindications) Ideal Candidates We generally follow standard medical guidelines for weight management, looking for: BMI of 30+ (Obesity): Individuals needing significant weight reduction for health
Induction of intestinal epithelial proliferation by glucagon-like peptide 2
Diarrhoea Diarrhoea is another potential side effect, as GLP-1 medications can alter the digestive process